Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca commences phase III trials for olaparib

AstraZeneca commences phase III trials for olaparib

5th September 2013

AstraZeneca has commenced a phase III clinical trial programme for olaparib, a promising new therapy for BRCA-mutated ovarian cancer.

The first patient has been enrolled in the Solo study programme, which is designed to determine the progression-free survival benefits of olaparib as a maintenance monotherapy among this patient demographic.

In the first trial, Solo 1, the drug will be assessed among patients who are in complete or partial response following platinum-based chemotherapy in the first-line setting, while the Solo 2 study will evaluate olaparib in the relapsed setting.

AstraZeneca originally decided not to move ahead with phase III trials of the drug in December 2011, but its new announcement means that it will be able to reverse a pre-tax impairment charge of $285 million (182.47 million pounds) that was incurred at the time.

Antoine Yver, vice-president and head of oncology at AstraZeneca's global medicines development unit, said: "We feel olaparib has real potential to significantly improve treatment decisions for this group of patients who currently have limited options, and to become the next important product in our growing oncology portfolio."ADNFCR-8000103-ID-801633912-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.